Ethan Daniel Borre, M.D.,Ph.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hearing Loss | 4 | 2024 | 780 | 1.650 |
Why?
|
| Deafness | 2 | 2023 | 457 | 1.270 |
Why?
|
| Hearing Aids | 1 | 2023 | 58 | 0.840 |
Why?
|
| Cochlear Implantation | 1 | 2022 | 315 | 0.620 |
Why?
|
| Cochlear Implants | 1 | 2022 | 338 | 0.610 |
Why?
|
| Patient Preference | 1 | 2024 | 922 | 0.560 |
Why?
|
| Burnout, Professional | 2 | 2023 | 702 | 0.530 |
Why?
|
| Quality-Adjusted Life Years | 4 | 2023 | 1724 | 0.530 |
Why?
|
| Thromboembolism | 2 | 2018 | 1017 | 0.490 |
Why?
|
| Dermatology | 2 | 2023 | 914 | 0.480 |
Why?
|
| Cost-Benefit Analysis | 10 | 2023 | 5508 | 0.480 |
Why?
|
| Patient Education as Topic | 1 | 2024 | 2315 | 0.460 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2024 | 1459 | 0.430 |
Why?
|
| Anti-HIV Agents | 5 | 2021 | 4491 | 0.360 |
Why?
|
| Mass Screening | 2 | 2022 | 5423 | 0.310 |
Why?
|
| Hearing | 2 | 2022 | 501 | 0.310 |
Why?
|
| Hemorrhage | 2 | 2018 | 3600 | 0.290 |
Why?
|
| Life Expectancy | 4 | 2023 | 1248 | 0.270 |
Why?
|
| Rubella Syndrome, Congenital | 1 | 2024 | 12 | 0.230 |
Why?
|
| Atrial Fibrillation | 2 | 2018 | 5209 | 0.210 |
Why?
|
| HIV Infections | 6 | 2019 | 17165 | 0.210 |
Why?
|
| Meningitis | 1 | 2024 | 218 | 0.200 |
Why?
|
| Otitis Media | 1 | 2024 | 285 | 0.190 |
Why?
|
| Budgets | 2 | 2019 | 230 | 0.170 |
Why?
|
| Uncertainty | 1 | 2022 | 754 | 0.150 |
Why?
|
| Receptor, Adenosine A1 | 1 | 2017 | 42 | 0.140 |
Why?
|
| Antimalarials | 1 | 2024 | 906 | 0.140 |
Why?
|
| Stroke | 2 | 2018 | 9962 | 0.140 |
Why?
|
| Fetal Blood | 1 | 2023 | 1343 | 0.130 |
Why?
|
| Adult | 9 | 2024 | 219994 | 0.130 |
Why?
|
| Quality of Life | 3 | 2023 | 13308 | 0.130 |
Why?
|
| Workload | 1 | 2021 | 847 | 0.130 |
Why?
|
| Hypothermia | 1 | 2017 | 188 | 0.130 |
Why?
|
| Drug Substitution | 1 | 2018 | 296 | 0.120 |
Why?
|
| Nutrition Surveys | 1 | 2022 | 1725 | 0.120 |
Why?
|
| Blood Coagulation | 1 | 2018 | 1157 | 0.100 |
Why?
|
| Drug Monitoring | 1 | 2018 | 965 | 0.100 |
Why?
|
| Humans | 18 | 2024 | 760621 | 0.100 |
Why?
|
| International Cooperation | 1 | 2017 | 1433 | 0.090 |
Why?
|
| Health Personnel | 1 | 2024 | 3310 | 0.090 |
Why?
|
| Middle Aged | 7 | 2024 | 220352 | 0.090 |
Why?
|
| Computer Simulation | 3 | 2019 | 6218 | 0.090 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2024 | 3986 | 0.080 |
Why?
|
| Cote d'Ivoire | 2 | 2019 | 64 | 0.080 |
Why?
|
| South Africa | 3 | 2021 | 1821 | 0.080 |
Why?
|
| Anti-Retroviral Agents | 1 | 2018 | 1779 | 0.080 |
Why?
|
| Risk | 1 | 2018 | 9631 | 0.070 |
Why?
|
| Health Care Costs | 2 | 2017 | 3258 | 0.070 |
Why?
|
| Health Policy | 1 | 2017 | 2677 | 0.060 |
Why?
|
| Child | 2 | 2023 | 79806 | 0.060 |
Why?
|
| Electronic Health Records | 1 | 2021 | 4775 | 0.060 |
Why?
|
| Anticoagulants | 1 | 2018 | 4897 | 0.050 |
Why?
|
| Aged | 3 | 2024 | 169152 | 0.050 |
Why?
|
| Zambia | 1 | 2021 | 257 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2023 | 42063 | 0.040 |
Why?
|
| United States | 2 | 2018 | 72461 | 0.040 |
Why?
|
| Female | 6 | 2024 | 391270 | 0.040 |
Why?
|
| Male | 5 | 2024 | 359744 | 0.040 |
Why?
|
| Septal Occluder Device | 1 | 2018 | 126 | 0.040 |
Why?
|
| Adenosine A1 Receptor Agonists | 1 | 2017 | 13 | 0.040 |
Why?
|
| Adolescent | 2 | 2023 | 87810 | 0.040 |
Why?
|
| Child, Orphaned | 1 | 2016 | 55 | 0.030 |
Why?
|
| Antithrombins | 1 | 2018 | 313 | 0.030 |
Why?
|
| Models, Economic | 1 | 2019 | 719 | 0.030 |
Why?
|
| Atrial Appendage | 1 | 2018 | 292 | 0.030 |
Why?
|
| Caloric Restriction | 1 | 2017 | 296 | 0.030 |
Why?
|
| Locomotion | 1 | 2017 | 387 | 0.030 |
Why?
|
| Health Care Rationing | 1 | 2017 | 435 | 0.030 |
Why?
|
| Body Temperature | 1 | 2017 | 777 | 0.030 |
Why?
|
| Comparative Effectiveness Research | 1 | 2018 | 718 | 0.030 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2019 | 2569 | 0.030 |
Why?
|
| Health Resources | 1 | 2019 | 935 | 0.030 |
Why?
|
| Adenosine | 1 | 2017 | 834 | 0.020 |
Why?
|
| Disease Transmission, Infectious | 1 | 2017 | 558 | 0.020 |
Why?
|
| Cardiovascular Diseases | 1 | 2017 | 15757 | 0.020 |
Why?
|
| Models, Biological | 2 | 2019 | 9467 | 0.020 |
Why?
|
| India | 1 | 2018 | 2336 | 0.020 |
Why?
|
| Drug Costs | 1 | 2019 | 1185 | 0.020 |
Why?
|
| RNA, Viral | 1 | 2018 | 2838 | 0.020 |
Why?
|
| Viral Load | 1 | 2018 | 3322 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2018 | 3562 | 0.020 |
Why?
|
| Heart Rate | 1 | 2017 | 4179 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2017 | 6414 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2017 | 5075 | 0.010 |
Why?
|
| Young Adult | 2 | 2019 | 58741 | 0.010 |
Why?
|
| Smoking | 1 | 2017 | 9073 | 0.010 |
Why?
|
| Incidence | 1 | 2017 | 21392 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2017 | 22023 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2019 | 41335 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2019 | 65017 | 0.010 |
Why?
|
| Risk Factors | 1 | 2017 | 74359 | 0.010 |
Why?
|
| Animals | 1 | 2017 | 167963 | 0.000 |
Why?
|